Incyte Announces Full Results From Phase 3 TRuE-V Program Ev

Treatment with ruxolitinib cream (Opzelura) resulted in facial repigmentation at Week 24, characterized by a significant proportion of patients achieving =75% improvement from baseline in the facial

Related Keywords

Delaware , United States , Ohio , Erica Cech , Catalina Loveman , David Rosmarin , Christine Chiou , Jim Lee , European Academy Of Dermatology , Dermatology Department At Tufts Medical Center , Group Vice , Drug Administration , Exchange Commission , European Medicines Agency , Incyte Corporation , Vitiligo Area Scoring , Vitiligo Area Scoring Index , European Academy , Vitiligo Noticeability Scale , Group Vice President , Inflammation Autoimmunity , Vice Chair , Dermatology Department , Tufts Medical , Mississippi River , Incyte Dermatology , Looking Statements , Incyte , Nnounces , Bull , Results , Rom , Hase , True , Program , Valuating , Ruxolitinib , Cream , Opzelura , Patients , Ith , Vitiligo ,